Stock AnalizTeladoc Health, Inc. TDOC
Medical/Nursing Services · IPO 2015 · data as of November 13, 2026
Teladoc Health, Inc. (TDOC) is a healthcare company listed in the US with a market value of about $1.6B. In the twelve months to September 30, 2026 it had revenue of $2.5B and net income of -$155M, a net margin of -6.3%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (1/5).
Key numbers: a price to free cash flow of 6.1, 5-year revenue growth of 18% a year, a 5-year average ROIC of -80%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 33% below the current price.
Score: 2.0 / 5
Checks passed
- P/FCF below 20
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5B | $2.5B | $2.6B | $2.6B | $2.4B | $2.0B | $1.1B | $553M | $418M | $233M | $123M |
| Net income | -$155M | -$200M | -$1.0B | -$220M | -$13.7B | -$429M | -$485M | -$99M | -$97M | -$107M | -$74M |
| Free cash flow | $262M | $285M | $283M | $339M | $173M | $185M | -$58M | $26M | -$9M | -$37M | -$54M |
| EPS (diluted) | $-0.86 | $-1.14 | $-5.87 | $-1.34 | $-84.60 | $-2.73 | $-5.36 | $-1.38 | $-1.47 | $-1.93 | $-1.75 |
| Net margin | -6.3% | -7.9% | -39.0% | -8.5% | -567.5% | -21.1% | -44.4% | -17.9% | -23.2% | -45.8% | -60.3% |
| ROIC | — | -9.2% | -31.9% | -5.0% | -350.5% | -1.2% | -2.5% | -4.9% | -3.9% | -9.8% | -18.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 18 analysts is $8.81, 0% above the current price; targets range from $6.00 to $11.50; the consensus rating is “Hold”; expected EPS is $-0.71 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Teladoc Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 33% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Teladoc Health pay a dividend?
Not currently.
Is Teladoc Health a good stock to buy?
We do not give buy or sell advice. Teladoc Health scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.